Help researchers understand Oregon’s cancer needs
A new survey from the OHSU Knight Cancer Institute aims to help researchers understand the cancer-related needs of Oregonians and inform ways to address those needs across the state. Figure:...
Tag: tyrosine kinase inhibitor
Targeting osteosarcoma, a cancer more common in young people
Knight Cancer researchers describe positive results with the drug regorafenib. Osteosarcoma is a bone cancer that disproportionately affects teenagers, and despite substantial efforts, outcomes for...
Positive results with a targeted therapy for osteosarcoma, a cancer more common in young people
Osteosarcoma is a bone cancer that disproportionately affects teenagers, and outcomes for patients have changed little in decades. Now researchers, including two OHSU Knight Cancer Institute...
Study reveals factors outside of tumors that steer breast cancer aggressiveness
Cancer researchers have identified key factors in the surroundings of tumor cells that it may be possible to target to improve outcomes for patients with HER2-positive breast cancer. Co-principal...
How to retarget cancers that have evaded targeted therapy
Targeted therapy drugs transformed the outlook for people with the rare cancers known as gastrointestinal stromal tumors, enabling some to survive a decade or longer. A fraction of GIST patients,...
The cancer drug that “changed everything”
Understanding the earliest drivers of cancer formation can lead to less toxic and more effective treatments. It transformed the outlook for people diagnosed with chronic myeloid leukemia. A...